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Abstract: This study evaluated the relationship between natriuretic peptide levels and a wide 
range of echocardiography parameters in a population of thirty-three patients with poorly 
regulated type 2 diabetes, and no known heart failure. Natriuretic peptides brain natriuretic 
peptide (BNP) and N-terminal prohormone BNP (NT-proBNP) were measured. Transthoracic 
echocardiography was performed and cardiac volumes and ejection fraction were measured. 
Doppler and tissue Doppler were measured and diastolic function was stratified according 
to recent guidelines. Very few echocardiography parameters were correlated with BNP or 
NT-proBNP levels. However, left atrial end-systolic volume indexed for body surface area 
was correlated with natural logarithm (ln) BNP and ln NT-proBNP (r = 0.62 and r = 0.60; 
P  0.05). There were significant differences in ln BNP and ln NT-proBNP levels between 
those with normal and those with abnormal diastolic function (1.4 vs 3.1; P  0.001 and 3.4 vs 
5.8; P  0.001). This study showed that very few echocardiography parameters were correlated 
with BNP or NT-proBNP levels in patients with poorly regulated type 2 diabetes, which in 
part contradicts previous studies in other diabetic populations. The exception was left atrial 
end-systolic volume that showed a moderate correlation with BNP or NT-proBNP levels. There 
were significant differences in BNP and NT-proBNP levels between the group with normal 
left ventricular diastolic function and the group with abnormal diastolic function.
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Introduction
Patients with type 2 diabetes (T2D) have an enhanced risk of contracting cardiovascular 
diseases.1–3 Much of the cardiovascular morbidity and mortality is driven by conges-
tive heart failure (CHF). It is important, therefore, to identify early those who have 
subclinical heart dysfunction. Biomarkers such as brain natriuretic peptide (BNP) and 
N-terminal prohormone  BNP (NT-proBNP) have been suggested as a screening tool 
in a variety of cardiac conditions.4–8
Patients with poorly regulated T2D are of special interest as they are candidates 
for add-on therapy with either insulin and/or thiazolidinediones,9 which may cause 
fluid retention, weight gain, and in a few cases, CHF.10 Moreover, previous studies 
examining the relationship between BNP and NT-proBNP versus echocardiography 
in diabetic patients have given diverging findings.11–14 This could, in part, be due to 
different diabetic populations and diverging echocardiography protocols.
There are no studies, to our knowledge, that have investigated the correlation 
between natriuretic peptide levels and the wide range of prognostic echocardiography 
parameters in a population of patients with poorly regulated T2D and no known Vascular Health and Risk Management 2010:6 374
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congestive heart disease. The present study thus evaluated 
the relationships between natriuretic peptides and a variety 
of echocardiography parameters in such a population.
Material and methods
Patients
Thirty-three consecutive patients with T2D and inadequate 
glycemic control, without known heart failure, were included 
in the study. Inadequate glycemic control was defined as 
treatment with metformin and sulfonylurea/meglitinide 
in doses 50% of maximum recommended doses and 
hemoglobin A1c (HbA1c) 6.2% measured with Mono-S 
method (= 7% National Glycohemoglobin Standardization 
Program, NGSP). Height and body mass were measured, 
and body mass index (BMI) was calculated. Body surface 
area (BSA) was calculated as (height in cm) 0.725 × (body 
mass in kg) 0.425 × 0.00718.15 Blood samples for the 
measurement of BNP and NT-proBNP were collected after 
at least 10 minutes rest in the supine position. All blood 
samples were drawn after an overnight fast. Estimated 
glomerular filtration rate (eGFR) was calculated according to 
the Cockroft–Gaults formula. Blood pressure was measured 
in the right arm after 5 minutes rest in the supine position. 
Exclusion criteria were clinical signs of heart failure accord-
ing to New York Heart Association (NYHA) or the pres-
ence of a heart murmur on auscultation. Echocardiography 
exclusion criteria were an inappropriate acoustic window 
or nonsinus rhythm. In the study population, three patients 
have had previous myocardial infarct and one patient had 
undergone a prior coronary artery bypass graft (CABG). 
Written informed consent was obtained from all participat-
ing patients. The institutional ethics committee of the Lund 
University, Sweden, approved the study.
Echocardiography
Transthoracic echocardiography examinations were 
performed with Sonos 5500 (Philips, Andover, MA, USA). 
A single observer blinded to all clinical data performed all 
echocardiography measurements, which were performed 
twice. The mean value was used in all analysis. From 
two dimensional (2-D) echocardiography, left ventricular 
end-diastolic diameter (LVDD), posterior wall thick-
ness (POST) and interventricularseptum thickness (IVS) 
were measured and left ventricular mass (LVM) was 
calculated from the formula LVM = 0.8 × 1.04 × (LVDD 
+ IVS + POST)3 - LVDD3 + 0.6.16 Left ventricular end-
diastolic volume (LVDV), left ventricular end-systolic 
volume (LVSV) and left atrial end-systolic volume (LAV) 
were quantified by biplane method of discs. All volume 
measurements, LVM, POST and IVS were indexed for BSA 
(LVDVI, LVSVI, LAVI, LVMI, POSTI, IVSI). Ejection 
fraction (EF) was quantified by biplane method of discs.16
Pulsed Doppler parameters were measured from the 
apical four chamber view at the tip of the mitral leaflets 
and peak of early diastolic (E) and late diastolic (A) mitral 
flow velocities. E/A ratio, and deceleration time (DT) of 
E-wave were measured. Pulmonary veins were viewed from 
the apical four chamber view and the pulmonary vein peak 
velocities during systole (S) and diastole (D) were measured 
with pulsed Doppler. S/D ratio was calculated.
Pulsed tissue Doppler imaging (TDI) of the medial and 
lateral mitral annulus was obtained from the apical four 
chamber view. Peak systolic (Sm), early (Em) and late (Am) 
mitral annular diastolic velocities were measured both at the 
septal and lateral annulus. The ratios for Em/Am and E/Em 
were calculated, with Em averaged from septal and lateral 
wall. TDI of the free right ventricular wall was obtained in the 
tricuspid annulus and Sm, Em, and Am were measured.
The subject’s left ventricular diastolic function was 
classified according to recent guidelines and graded from 1 to 4, 
with grade 1 representing normal and grade 2–4 representing 
escalating degrees of abnormal diastolic function.17 We based 
our grading of diastolic function on the following variables: 
Em, LAVI, E/A, and DT.17
The subject’s left ventricular filling pressure was 
estimated according to recent guidelines and classified as 
normal or elevated.17 We based our estimation of filling pres-
sure on E/Em and LAVI.17
Assays
BNP was measured with an immunoassay system from 
Beckman (Biosite, CA, USA) with a coefficient of variance 
(CV) of 3.5% and NT-proBNP using an immunometric 
method (Hitachi Modular-E; Roche, Mannheim, Germany) 
with a CV of 4.4%.
Statistical methods
Data are presented as means ± SD. Statistical analyses were 
carried out using Statistica 7.1 (StatSoft Inc, Tulsa, OK, 
USA). Skewed values were normalized by ln, values without 
logarithmic transformation are also presented for the sake of 
simplicity. Univariate relationships between ln BNP or ln 
NT-proBNP and various variables were assessed with Pearson 
correlation analysis, with adjustment made for sex. Stepwise 
multiple forward regression analyses, with intercept, were 
used to evaluate the independency in the relationship between Vascular Health and Risk Management 2010:6 375
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BNP or NT-proBNP versus LAVI. In these models, BNP or 
NT-proBNP were dependent variables and LAVI, age, body 
mass, and sex were introduced into the model as independent 
variables. Receiver-operator characteristic analysis was not 
performed due to the limited number of subjects. Student’s 
t-test between means was used to analyse group differences. 
Statistical significance was set at a level of P  0.05.
Results
All subjects had acceptable measurements and an EF  50%. 
No patient had significant valve disease. Table 1 displays 
descriptive statistics of the study population. BNP and 
NT-proBNP showed very little correlation with the various 
echocardiography parameters. Table 2 displays Pearson 
correlation coefficients between ln BNP and ln NT-proBNP 
versus the echocardiography parameters. The salient 
exception was LAVI, which showed a moderate relationship 
with both BNP and NT-proBNP levels. Multiple regression 
analyses indicated that LAVI alone explained 35% of the 
variance in BNP concentrations (r2 = 0.35), whereas the other 
variables that entered the model added nothing significant. 
A similar result was found for NT-proBNP concentrations 
(r2 = 0.33), where LAVI alone explained 33% of the 
variance with the other variables adding nothing significant. 
Figures 1 and 2 display the unadjusted relationship between 
LAVI versus ln BNP and ln NT-proBNP.
A total of 29 subjects had grade 1 diastolic function 
(normal), two had grade 2, and two had grade 3. The 
individuals who had grade 2 and 3 were pooled together 
as abnormal in further analyses. There were significant 
differences between these groups, despite the modest sample 
size. Ln BNP and ln NT-proBNP levels for those with normal 
and for those with abnormal diastolic function were 1.4 vs 3.1 
(P  0.001) and 3.4 vs 5.8 (P  0.001), respectively. Table 3 
is a summary of anthropometric, laboratory,  and selected 
echocardiography characteristics for those with normal ver-
sus those with abnormal diastolic function. Figures 3 and 4 
displays the ln BNP and ln NT-proBNP values according to 
diastolic function.
A total of 25 subjects had normal filling pressure, as 
estimated by echocardiography, and eight subjects had 
indications of elevated filling pressure. There were no 
significant differences between those with normal compared 
to those with elevated filling pressure; ln BNP 1.5 vs 1.9 and 
in NT-proBNP 3.5 vs 4.0, P  0.20 for both. Table 4 is a 
summary of anthropometric, laboratory, and selected echo-
cardiography characteristics for those with normal versus 
those with elevated filling pressure.
Table 1 Subjects’ anthropometric, echocardiography and laboratory 
characteristics. Values are mean ± SD
Men/women 23/10
Age (yrs) 61.4 ± 7.4
Height (cm) 170.9 ± 9.0
Body mass (kg) 90.4 ± 16.5
BMI (kg/m2) 31.0 ± 5.6
BSA (m2) 2.0 ± 0.2
Diabetes duration (years) 9.8 ± 6.2
HbA1c (%) 8.2 ± 1.4
Systolic blood pressure (mm Hg) 144 ± 17
Diastolic blood pressure (mm Hg) 83 ± 8
BNP (pmol/l) 7.8 ± 9.3
eGFR (ml/min) 117 ± 39
NT-proBNP (ng/l) 86 ± 123
LVMI (g/m2) 82 ± 17
LVDVI (ml/m2) 50 ± 8
LVSVI (ml/m2) 19 ± 4
LAVI (ml/m2) 27 ± 6
IVSI (mm/m2) 5.1 ± 0.5
POSTI (mm/m2) 4.5 ± 0.4
EF (%) 63 ± 5
E (cm/s) 76 ± 20
A (cm/s) 84 ± 19
E/A 0.9 ± 0.3
DT (msec) 218 ± 44
S (cm/s) 64 ± 10
D (cm/s) 49 ± 14
S/D 1.4 ± 0.3
Sm septal (cm/s) 7.6 ± 1.6
Em septal (cm/s) 6.7 ± 1.4
Am septal (cm/s) 9.6 ± 1.8
Sm lateral (cm/s) 8.9 ± 1.6
Em lateral (cm/s) 8.7 ± 2.6
Am lateral (cm/s) 11.4 ± 2.5
E/Em 10.3 ± 3.7
Em/Am septal 0.7 ± 0.2
Em/Am lateral 0.8 ± 0.3
Em/Am average 0.7 ± 0.2
Sm right ventricle (cm/s) 13.6 ± 3.0
Em right ventricle (cm/s) 9.8 ± 2.9
Am right ventricle (cm/s) 14.5 ± 3.1
Abbreviations: BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro 
brain natriuretic peptide. Indexed for BSA: POSTI, posterior wall thickness;   
IVSI, interventricularseptum thickness; LVMI, left ventricular mass; LVDVI, left 
ventricular end-diastolic volume; LVSVI, left ventricular end-systolic volume; 
LAVI, left atrial end-systolic volume; EF, ejection fraction; E, peak of early dia-
stolic; A, late diastolic; mitral flow velocities. DT, deceleration time of E-wave; 
S, Pulmonary vein peak velocities systole; D, diastole. pulsed tissue Doppler 
imaging velocities; Sm, peak systolic; Em, early diastolic velocities; Am, late 
diastolic velocities.Vascular Health and Risk Management 2010:6 376
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Table 2 Pearson correlation coefficients, with adjustment for sex, 
between in BNP and in NT-proBNP versus anthropometric and 
echocardiography parameters
Echocardiography parameter ln BNP ln NT -proBNP
Age (yrs) 0.04 0.27
Height (cm) 0.09 0.02
Body mass (kg) 0.36* 0.17
BMI (kg/m2) 0.32 0.14
BSA (m2) 0.33 0.16
eGFR (ml/min) 0.18 -0.09
LVMI (g/m2) 0.11 0.33
LVDVI (ml/m2) 0.32 0.16
LVSVI (ml/m2) 0.22 0.16
LAVI (ml/m2) 0.62** 0.60**
IVSI (mm/m2) -0.31 0.20
POSTI (mm/m2) -0.25 0.06
EF (%) -0.05 -0.10
E 0.25 0.25
A -0.12 0.16
E/A 0.30 0.08
DT -0.17 -0.24
S 0.02 0.19
D 0.25 0.29
S/D -0.29 -0.18
Sm septal -0.21 -0.11
Em septal 0.15 0.18
Am septal -0.24 -0.21
Sm lateral -0.29 -0.11
Em lateral -0.05 -0.07
Am lateral -0.05 0.07
E/Em 0.10 0.14
Em/Am septal 0.31 0.32
Em/Am lateral -0.05 -0.11
Em/Am average 0.09 0.03
S right ventricle 0.08 0.13
Em right ventricle 0.25 0.15
Am right ventricle -0.08 -0.00
Notes: *Indicate statistical significant correlation, P  0.05 and **P  0.001. Indexed 
for BSA.
Abbreviations: POSTI, posterior wall thickness; IVSI, interventricularseptum 
thickness; LVMI, left ventricular mass; LVDVI, left ventricular end-diastolic volume; 
LVSVI, left ventricular end-systolic volume; LAVI, left atrial end-systolic volume; EF, 
ejection fraction; E, peak of early diastolic; A, late diastolic; mitral flow velocities. 
DT, deceleration time of E-wave; S, pulmonary vein peak velocities systole; D, dias-
tole. pulsed tissue Doppler imaging velocities: Sm, peak systolic; Em, early diastolic 
velocities; Am, late diastolic velocities.
Discussion
This study showed that very few echocardiography 
parameters were correlated with BNP or NT-proBNP levels 
in patients with poorly regulated type 2 diabetes, which partly 
contradicts previous studies in other diabetic populations. 
The exception was LAVI, which showed moderate correlation 
with BNP or NT-proBNP levels. The relatively strong 
correlations that were found, in spite of the modest sample 
size, suggests a biologically relevant relationship. Further-
more, significant differences in BNP and NT-proBNP levels 
were found between the group with normal left ventricular 
diastolic function and the group with abnormal diastolic 
function. In contrast, no significant differences in BNP 
and NT-proBNP levels were found between the individuals 
with normal versus elevated filling pressures, as estimated 
by echocardiography. These findings should of course be 
viewed with a considerable amount of caution because of 
the modest sample size, but they do point out directions for 
further larger studies.
BNP and NT-proBNP, being peptide hormones released 
from the cardiac ventricles in response to myocyte stretch, 
have generated considerable attention in recent years and have 
been proposed as potential diagnostic and prognostic markers 
for cardiac disease. Natriuretic peptides are shown to correlate 
with measures of cardiac dysfunction. NT-proBNP also have 
been shown to be independent risk markers for cardiovascular 
disease in patients with diabetes.18–20 For example, a reduction 
of 10 pg/mL in NT-proBNP is associated with a 1% relative 
reduction in the cardiovascular endpoints in patients with 
type 1 diabetes and microalbuminuria.19
It is somewhat surprising that none of the Doppler 
and tissue Doppler parameters were related to BNP and 
NT-proBNP concentrations. This could, in part, be related 
to the known U-shape of most diastolic variables, with the 
exception of Em and E/Em. Additionally, the modest sample 
size could be a factor since several of the correlations went 
in the hypothesized direction but did not reach statistical 
significance. Equally surprising was the finding that very few 
patients were diagnosed with diastolic dysfunction, which 
could be explained by the heavy reliance on LAVI in the 
current classification of diastolic dysfunction. Whether this 
classification will survive the test of time remains to be seen. 
The finding that LAVI was moderately related to BNP and 
NT-proBNP levels is of interest since LAVI has been found 
to be a potent prognosticator in a variety of cardiac disorders 
and in the general population.21 Furthermore, LAVI has been 
suggested to serve as an expression of left ventricular filling 
pressures in individuals without atrial fibrillation or mitral 
valve disease.21 The underlying mechanism is that the left 
atrium is exposed to the pressures of the left ventricle during 
diastole. With increased stiffness or lack of compliance in 
the left ventricle the pressure rises to maintain adequate 
left ventricular filling, which leads to increased atrial wall Vascular Health and Risk Management 2010:6 377
Natriuretic peptides and echocardiography in type 2 diabetes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
15 20 25 30 35 40 45 50
−1
0
1
2
3
4
5
LAVI
I
n
 
B
N
P
Figure 1 The figure displays the unadjusted relationship between left atrial end-systolic volume indexed for body surface area (BSA) indexed left atrial end-systolic volume 
(LAVI) and ln brain natriuretic peptide (ln BNP).
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Figure 2 The figure displays the unadjusted relationship between left atrial end-systolic volume indexed for body surface area (BSA) indexed left atrial end-systolic volume 
(LAVI) and ln N-terminal pro brain natriuretic peptide (ln NT-proBNP).Vascular Health and Risk Management 2010:6 378
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tension and subsequent dilatation. Moreover, LAVI has been 
suggested to better express the long standing exposure to 
elevated filling pressures caused by left ventricular diastolic 
dysfunction than more load dependent parameters such as 
Doppler and TDI.21 This aspect could in part explain why 
no significant differences in BNP and NT-proBNP levels 
were found between the individuals with normal versus 
elevated filling pressures. The initial validation studies of 
the E/Em index as a way of estimating filling pressure by 
echocardiography were very promising.22–24 A recent study 
has, however, raised significant concern about the use of the 
E/Em index for estimation of filling pressures.25 Moreover, 
the E/Em index has not been validated, as a estimate of filling 
pressure, in diabetic populations.22–25
We have been able to identify four previous studies 
examining the relationship between BNP and NT-proBNP 
Table 3 Subjects’ anthropometric, laboratory, and selected echocardiography characteristics. Values are mean ± SD
Variable Normal Abnormal P-value
Men/women 20/9 3/1 0.2
Age (yrs) 60.9 ± 7.3 65.3 ± 7.3 0.2
Height (cm) 170.4 ± 9.1 174.3 ± 9.1 0.2
Body mass (kg) 89.3 ± 16.8 98.5 ± 16.8 0.2
BMI (kg/m2) 30.8 ± 5.6 32.7 ± 5.6 0.2
BSA (m2) 2.0 ± 0.2 2.1 ± 0.2 0.2
Diabetes duration (years) 9.1 ± 5.3 15.0 ± 5.3 0.08
HbA1c (%) 8.1 ± 1.3 9.0 ± 1.3 0.2
Systolic blood pressure (mm Hg) 141.1 ± 15.3 161.0 ± 15.4 0.02
Diastolic blood pressure (mm Hg) 82.0 ± 7.8 86.5 ± 7.8 0.2
eGFR (ml/min) 118 ± 40 116 ± 38 0.20
BNP (pmol/l) 5.3 ± 3.4 26.0 ± 3.4 0.001
ln BNP 1.4 ± 0.8 3.1 ± 0.8 0.001
NT-proBNP (ng/l) 48.3 ± 47.4 360.0 ± 47.4 0.001
ln NT-proBNP 3.4 ± 1.1 5.8 ± 1.1 0.001
LVMI (g/m2) 80.7 ± 16.6 93.2 ± 16.6 0.17
LVDVI (ml/m2) 49.4 ± 7.8 56.8 ± 7.8 0.07
LVSVI (ml/m2) 18.3 ± 4.3 21.1 ± 4.3 0.20
LAVI (ml/m2) 25.2 ± 4.1 38.9 ± 4.1 0.001
IVSI (mm/m2) 5.1 ± 0.4 5.2 ± 0.4 0.2
POSTI (mm/m2) 4.5 ± 0.4 4.5 ± 0.4 0.2
EF (%) 63.1 ± 5.2 63.0 ± 5.2  0.2
E/A 0.9 ± 0.3 1.1 ± 0.3 0.2
DT (msec) 219 ± 44 211 ± 44 0.2
S/D 1.4 ± 0.3 1.2 ± 0.3 0.2
E/Em 10.0 ± 3.6 12.5 ± 3.6 0.20
Sm septal (cm/s) 7.6 ± 1.7 7.2 ± 1.7 0.2
Em septal (cm/s) 6.7 ± 1.4 7.0 ± 1.4 0.2
Am septal (cm/s) 9.7 ± 1.8 8.2 ± 1.8 0.09
Sm lateral (cm/s) 9.1 ± 1.5 7.5 ± 1.5 0.07
Em lateral (cm/s) 8.8 ± 2.7 8.3 ± 2.7 0.2
Am lateral (cm/s) 11.6 ± 2.4 9.8 ± 2.4 0.19
Notes: The study population is divided into those with normal versus abnormal diastolic function.
Abbreviations: BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro brain natriuretic peptide. Indexed for BSA: POSTI, posterior wall thickness; IVSI, interventricu-
larseptum thickness; LVMI, left ventricular mass; LVDVI, left ventricular end-diastolic volume; LVSVI, left ventricular end-systolic volume; LAVI, left atrial end-systolic volume; 
EF, ejection fraction; E, peak of early diastolic; A, late diastolic; mitral flow velocities. DT, deceleration time of E-wave; S, pulmonary vein peak velocities systole; D, diastole. pulsed 
tissue Doppler imaging velocities; Sm, peak systolic; Em, early diastolic velocities; Am, late diastolic velocities.Vascular Health and Risk Management 2010:6 379
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Figure 3 The figure displays the study population according to classification of left ventricular diastolic function and levels of ln brain natriuretic peptide (ln BNP).
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Figure 4 The figure displays the study population according to classification of left ventricular diastolic function and levels of ln N-terminal pro brain natriuretic peptide   
(ln NT-proBNP).Vascular Health and Risk Management 2010:6 380
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Table 4 Subjects’ anthropometric, laboratory, and selected echocardiography characteristics
Variable Normal Elevated P-value
Men/women 19/6 4/4 0.17
Age (yrs) 61.5 ± 7.1 61.0 ± 8.9 0.20
Height (cm) 172 ± 7 167 ± 10 0.13
Body mass (kg) 90 ± 17 93 ± 15 0.20
BMI (kg/m2) 30.1 ± 5.0 33.7 ± 6.8 0.12
BSA (m2) 2.0 ± 0.2 2.0 ± 0.2 0.20
Diabetes duration (years) 9.0 ± 5.9 12.5 ± 7.1 0.17
HbA1c (%) 7.9 ± 1.0 9.2 ± 2.0 0.02
Systolic blood pressure (mm Hg) 142 ± 17 147 ± 17 0.20
Diastolic blood pressure (mm Hg) 82 ± 8 83 ± 5 0.20
eGFR (ml/min) 114 ± 36 129 ± 51 0.20
BNP (pmol/l) 6.5 ± 5.9 11.9 ± 15.9 0.16
ln BNP 1.5 ± 0.9 1.9 ± 1.2 0.20
NT-proBNP (ng/l) 74 ± 115 123 ± 149 0.20
ln NT-proBNP 3.5 ± 1.3 4.0 ± 1.5 0.20
LVMI (g/m2) 83.7 ± 16.5 77.6 ± 17.8 0.20
LVDVI (ml/m2) 50.4 ± 8.1 50.1 ± 7.0 0.20
LVSVI (ml/m2) 18.9 ± 4.5 18.0 ± 3.6 0.20
LAVI (ml/m2) 26.1 ± 6.0 29.4 ± 6.7 0.20
IVSI (mm/m2) 5.2 ± 0.4 4.9 ± 0.6 0.07
POSTI (mm/m2) 4.5 ± 0.4 4.3 ± 0.4 0.08
EF (%) 63 ± 5 64 ± 5 0.20
E/A 0.9 ± 0.3 1.0 ± 0.3 0.20
DT (msec) 222 ± 44 207 ± 44 0.20
S/D 1.4 ± 0.2 1.4 ± 0.4 0.20
E/Em 8.6 ± 1.7 15.6 ± 3.1 0.001
Sm septal (cm/s) 7.9 ± 1.7 6.7 ± 1.0 0.08
Em septal (cm/s) 7.0 ± 1.4 5.8 ± 1.2 0.03
Am septal (cm/s) 9.9 ± 1.7 8.4 ± 1.6 0.04
Sm lateral (cm/s) 9.2 ± 1.4 8.0 ± 1.8 0.07
Em lateral (cm/s) 9.3 ± 2.7 7.0 ± 1.8 0.04
Am lateral (cm/s) 11.2 ± 2.0 11.9 ± 3.7 0.20
Notes:   Values are mean ± SD. The study population is divided into those with normal versus elevated filling pressure estimated by echocardiography.
Abbreviations: BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro brain natriuretic peptide. Indexed for BSA: POSTI, Pposterior wall thickness; IVSI, interventricularseptum 
thickness; LVMI, left ventricular mass; LVDVI, left ventricular end-diastolic volume; LVSVI, left ventricular end-systolic volume; LAVI, left atrial end-systolic volume; EF, ejection 
fraction; E, peak of early diastolic; A, late diastolic; mitral flow velocities. DT, deceleration time of E-wave; S, pulmonary vein peak velocities systole; D, diastole. pulsed tissue 
Doppler imaging velocities; Sm, peak systolic; Em, early diastolic velocities;   Am, late diastolic velocities.
versus echocardiography in diabetic patients.11–14 These 
studies consist of diverging diabetic populations and 
diverging echocardiography protocols. Epshteyn et al 
investigated a mixed US population of 486 patients, 88% 
T2D and 12% type 1 diabetes.13 Raised BNP levels were 
found to predict abnormal left ventricular function defined 
as EF  50% or abnormal diastolic function based solely 
on Doppler findings. Fang et al studied 101 unselected 
asymptomatic patients with T2D.11 In this study, subclinical 
left ventricular disease as measured by Doppler and 
tissue Doppler could not be predicted by BNP. Similar 
findings were found by Valle et al, who investigated 
79 T2D patients without known heart disease.12 In con-
trast, Shimabukuro et al found that BNP levels could 
predict left ventricular diastolic dysfunction, as measured 
only by Doppler, in 98 T2D patients without known heart Vascular Health and Risk Management 2010:6 381
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disease.14 The relationship between LAVI or the current 
classification of left ventricular diastolic function and BNP 
and NT-proBNP concentration has not been investigated 
in previous studies.11–14
Echocardiography is considered a “gold standard” 
method, in daily clinical practice, for evaluating cardiac 
function. However, due to its limited availability and costs, it 
is not possible to use in larger groups of patients. Natriuretic 
peptides on the other hand are readily available and relatively 
inexpensive. There is consensus that natriuretic peptides are 
useful in screening for cardiovascular disease, especially in 
symptomatic patient populations.6
Furthermore, natriuretic peptides carry powerful 
prognostic information.6 There are, however, currently 
no clear algorithms on how these biomarkers should be 
implemented into clinical practice in patients with T2D. 
In a population of patients with type 2 diabetes and drug 
failure (the subjects of this study) there is a need for 
combination therapy to achieve glycemic goals. Add 
on treatments with insulin and/or thiazolidinediones are 
among common treatment strategies.9 However, these 
regimens may cause fluid retention, weight gain, and in 
a few cases, heart failure. Our results support, in part, 
an initial assessment of a natriuretic peptide to identify 
individuals who have preexisting heart dysfunction, despite 
the modest sample size.
Conclusion
This pilot study showed that very few echocardiography 
parameters correlated with BNP or NT-proBNP levels 
in a population of patients with poorly regulated T2D. 
The exception was LAVI, which showed a moderate 
correlation with BNP or NT-proBNP levels. Moreover, 
significant differences in BNP and NT-proBNP levels were 
found between those with normal and those with abnormal 
left ventricular diastolic function according to current 
classifications. Larger studies are warranted to confirm these 
findings. There is a need for tools to help clinicians to risk 
stratify subsets of patients who are likely to have particularly 
unfavorable prognoses, using readily identifiable clinical and 
laboratory factors. Knowledge is increasing in this field and, 
hopefully, the results will enable clinicians to identify patients 
with increased risk of developing adverse events, thereby 
choosing an individualized treatment and monitoring scheme 
for each patient. Data on patients with poorly regulated T2D 
are scarce and the findings in the present investigation points 
out a direction for further larger studies.
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